Aug 2026· Cancer Genomics & Proteomics· Vol 23, pp. 1043 - 1060· 0 citations· 28 references
Medicine
TL;DR
T-cell abundance and immune effectiveness can be uncoupled in MSS CRC, and a molecular case report shows that T-cell abundance and immune effectiveness can be uncoupled in MSS CRC.
Abstract
Abstract Background/Aim: Microsatellite-stable (MSS) colorectal cancer (CRC) generally responds poorly to immune checkpoint blockade, but some MSS tumors are T-cell rich. We examined whether such infiltration reflected effective immunity or functional immune constraint. Case Report: A 77-year-old woman underwent resection of a mismatch repair-proficient (pMMR), MSS, low-mutational-burden CRC with a synchronous adenoma. Whole-exome sequencing of tumor, adenoma and adjacent normal tissue detected no shared high-confidence somatic mutations between tumor and adenoma within the sensitivity of this WES analysis and identified tumor-specific APC, KRAS and TP53 alterations. Tumor single-cell RNA sequencing yielded 7,569 cells, with T-lineage populations comprising 83.5%. Cytotoxic T cells showed cytolytic and dysfunction-associated features, regulatory T cells (Tregs) showed suppressive remodeling, and Th17 cells showed inflammatory/profibrotic programs. CellChat nominated stromal MIF/FN1-CD74/CD44 and extracellular-matrix communication with T-cell compartments. Conclusion: This molecular case report shows that T-cell abundance and immune effectiveness can be uncoupled in MSS CRC.
Microsatellite-stable (MSS) colorectal cancer (CRC) accounts for approximately 85% of all CRC cases and exhibits limited responsiveness to immune checkpoint inhibitors (ICIs), representing a major challenge in current cancer immunotherapy. At the tumor-cell intrinsic level, low tumor mutational burden (TMB), impaired n...
Dong-Guang Niu, Peng Liu, Xin-Yu Chen et al.· Frontiers in Oncology· 0 citations
These findings identify a tumor-adapted MC state that orchestrates immune evasion and tissue remodeling during CRC progression, supporting the notion that MC are reprogrammed toward an immune-suppressive and pro-tumorigenic phenotype.
E. Putro, Alessia Carnevale, Caterina Marangio et al.· Cell Death & Disease· 0 citations
The recent approval of covalent KRAS G12C inhibitors, sotorasib and adagrasib, has revealed that targeted KRAS blockade can remodel the TME toward an immunostimulatory state, providing a mechanistic rationale for combining KRAS-directed agents with immune checkpoint blockade, STING agonists, and neoantigen vaccines.
Vasudevan Ramachandran, H. L. Koyou, Siddarth Raajasekar et al.· Frontiers in Oncology· 0 citations
Microsatellite-stable (MSS) colorectal cancer (CRC), comprising ~85–90% of cases, remains almost universally refractory to PD-1/PD-L1 monotherapy (objective response rate 5–10%), in stark contrast to the marked efficacy of immune checkpoint inhibitors (ICIs) in microsatellite-instability-high (MSI-H) disease. Here we s...
Zhi-Yuan Xia, Hai-Ning Chen, Ye-Fu Shen et al.· Frontiers in Immunology· 0 citations
Pancreatic cancer (PC) is largely refractory to immune checkpoint blockade (ICB), although homologous recombination-deficient (HRD) tumors may derive benefit. In the POLAR trial of maintenance pembrolizumab plus olaparib after platinum-based chemotherapy for metastatic PC, responses remained heterogeneous. To define de...
M. Hilmi, J. Schoenfeld, Wilson H. McKerrow et al.· bioRxiv· 0 citations
Introduction Colorectal cancer (CRC) comprises heterogeneous malignant epithelial states, but it remains unclear which transcriptional programs recur across patients and how these programs relate to the immune context. Methods We integrated five public single-cell RNA-sequencing datasets comprising 425,402 cells from 1...
Wei-Xue Ying, Yu-Han Zhang, Shi-Rong Wu et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.